2023-06-27 23:00:13
According to the HelloSafe platform, Mexico is the second country with the highest prevalence of diabetes in Latin America.
The new ultra-rapid-acting insulin approved by Cofepris is indicated for people over one year of age with type 1 diabetes.
In the medium and long term, the risk of microvascular complications, such as albuminuria and retinopathy, decreases; and macrovascular complications, such as heart attack.
Diabetes has become one of the most alarming public health problems in Mexico. In just a few decades there has been an exponential increase in cases and the trend continues to rise. Therefore it is of great importance that the Federal Commission for the Protection against Sanitary Risks (Cofepris) authorized a new ultra-rapid acting insulin.
Before beginning, it should be remembered that this Commission was created in 2001 and was established as a decentralized administrative body of the Ministry of Health (SSa) with technical, administrative and operational autonomy. Since then, its main task is to be the governing body in matters of health control and regulation throughout the country.
For its part, there are three large sectors that it regulates: food, beverages and tobacco; health care articles; and personal care items. With this in mind, it regulates 44 cents of every peso spent by households in the country.
Diabetes in Mexico
On the other hand, in 2022 the HelloSafe platform published the results of a regional study that places Mexico as the second country with the highest prevalence of diabetes in Latin America.
The work indicates that there are 14 million adults between 20 and 79 years of age who have diabetes. Therefore, 13.5 percent of the population has this condition. Similarly, the research mentions that if the trend continues, diabetes will cost Mexican society more than 200 billion pesos in 2040.
Cofepris authorizes a new ultra-rapid-acting insulin
Having said the above, important news has now been released that will benefit all people who have this condition. The pharmacist Eli Lilly received authorization from Cofepris to use a new ultra-rapid-acting insulin for adult patients with diabetes and children with type 1 diabetes older than one year.
“Our goal has always been to provide therapeutic options that make life easier for people who have been diagnosed with diabetes. After a century of having begun with the commercialization and production of insulin as a treatment for the disease, the expectations of health and management of the disease have evolved to provide a better quality of life and radically and positively transform its care,” he said. Dr. Nuria Marcos, director of the Medical Area for Lilly Latin America.
How does it work?
The recently approved alternative allows a faster absorption of insulin into the bloodstream. This achieves a greater glycemic control after meals. At the same time, it provides less exposure to insulin, that is, after the third hour of application, the risk of late hypoglycemia in the patient decreases.
With the application of this insulin significantly reduces glycemic variability and post-meal glucose levels. Which, in the medium and long term, decreases the risk of microvascular complications, such as albuminuria and retinopathy; and macrovascular complications, such as heart attack. For this reason the Glucose control is essential in people living with diabetes.
Also read:
This is the first children’s center specialized in type 1 diabetes in Mexico
Diabetes in Mexico: Only 1 in 10 people undergo diagnostic tests
Cofepris Laboratory receives an important award for the accreditation of international standards
#Cofepris #authorizes #ultrarapidacting #insulin